Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuron (IMRN) Change in Cash (2016 - 2024)

Immuron's quarterly Change in Cash came in at -$2.6 million in Q4 2024, down 113.47% year-on-year from $19.3 million in Q1 2024, and down 113.47% quarter-over-quarter from -$1.2 million in Q4 2023.

Immuron has reported Change in Cash for 8 years, with the latest figure at -$2.6 million in Q4 2024.

  • For the quarter ending Q4 2024, Change in Cash fell 113.47% year-over-year to -$2.6 million; the trailing twelve-month figure through Dec 2024 stood at $16.5 million (down 12.27% YoY), and the FY2025 full-year result was -$8.8 million, down 59.19% from the prior year.
  • Change in Cash for Q4 2024 stood at -$2.6 million, down from -$1.2 million in the prior quarter.
  • The five-year high for Change in Cash was $23.9 million in Q4 2020, with the low at -$3.6 million in Q4 2022.
  • Average Change in Cash over 4 years is $4.1 million, with a median of -$1.9 million recorded in 2023.
  • Year-over-year, Change in Cash soared 8005.28% in 2020 and tumbled 113.47% in 2024.
  • Tracing IMRN's Change in Cash over 4 years: stood at $23.9 million in 2020, then slumped by 115.14% to -$3.6 million in 2022, then jumped by 66.28% to -$1.2 million in 2023, then plunged by 113.47% to -$2.6 million in 2024.
  • The last three Change in Cash figures came in at -$2.6 million (Q4 2024), -$1.2 million (Q4 2023), and -$3.6 million (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.44 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 623.00 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.44 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 417.10 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -153.10 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 53.61 Mn
10 Immuron 1.27 Bn 1.27 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -2.60 Mn
Dec 31, 2023 -1.22 Mn
Dec 31, 2022 -3.62 Mn
Dec 31, 2020 23.89 Mn
Dec 31, 2019 -302,214.00
Dec 31, 2018 -424,901.00
Dec 31, 2017 -2.68 Mn
Dec 31, 2016 612,906.48